0001104659-22-010399.txt : 20220201 0001104659-22-010399.hdr.sgml : 20220201 20220201170651 ACCESSION NUMBER: 0001104659-22-010399 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220131 FILED AS OF DATE: 20220201 DATE AS OF CHANGE: 20220201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Varian John CENTRAL INDEX KEY: 0001416176 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33958 FILM NUMBER: 22579802 MAIL ADDRESS: STREET 1: ARYX THERAPEUTICS,INC. STREET 2: 6300 DUMBARTON CIRCLE CITY: FREMONT STATE: CA ZIP: 94555 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SELLAS Life Sciences Group, Inc. CENTRAL INDEX KEY: 0001390478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7 TIMES SQUARE STREET 2: SUITE 2503 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 6462005278 MAIL ADDRESS: STREET 1: 7 TIMES SQUARE STREET 2: SUITE 2503 CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: Galena Biopharma, Inc. DATE OF NAME CHANGE: 20110926 FORMER COMPANY: FORMER CONFORMED NAME: RXi Pharmaceuticals Corp DATE OF NAME CHANGE: 20110926 FORMER COMPANY: FORMER CONFORMED NAME: GALENA BIOPHARMA, INC. DATE OF NAME CHANGE: 20110922 4 1 tm225088-5_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-01-31 0 0001390478 SELLAS Life Sciences Group, Inc. SLS 0001416176 Varian John C/O SELLAS LIFE SCIENCES GROUP, INC., 7 TIMES SQUARE, SUITE 2503 NEW YORK NY 10036 1 0 0 0 Common Stock 2022-01-31 4 A 0 1900 0.00 A 1900 D Stock Option (Right to Buy) 5.34 2022-01-31 4 A 0 7125 0 A 2032-01-31 Common Stock 7125 7125 D The Reporting Person received an award of 1,900 restricted stock units on January 31, 2022, which shall vest in full on December 1, 2022, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. The shares subject to the option will fully vest on the earlier of (x) January 31, 2023 (the first anniversary of the date of grant) or (y) the business day prior to the 2023 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. /s/ John Varian 2022-02-01